Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01709214 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
A Phase 2 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 619
- Enrollment target
NCT01709214: Completed Phase 2 study, sponsored by Tris Pharma.
NCT01709214 is a Phase 2 study that has completed, run by Tris Pharma. The registered enrollment target is 619 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (365% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01709214, a Phase 2 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 619 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. This study includes a maximum 21 day Screening Period followed by a 15-week Double-blind Treatment Period and a 4-7 day Safety Follow-up period. Patients who are eligible for the Double-blind Treatment Period will be randomized to one of following treatment groups: GRT6005 high-dose range (400, 600 or 800 mcg), GRT6005 low-dose range (200, 300 or 400 mcg), oxycodone controlled release (CR) dose range (10, 20, 30, 40 or 50 mg) or placebo.
Interventions
- DRUG Placebo
- DRUG Oxycodone CR
- DRUG Cebranopadol (GRT6005) Low-Dose Range
- DRUG Cebranopadol (GRT6005) High-Dose Range
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 619 participants |
| Start Date | 2012-12-04 |
| Est. Completion | 2014-04-04 |
| Phase | Phase 2 |
What the finished NCT01709214 record still lists
NCT01709214 is an interventional study that assigns participants to a tested intervention. The registered 619 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (365% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01709214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01709214 about?
NCT01709214 is a clinical study titled "Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain". The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. This study includes a maximum 21 day Screening Period followed by a 15-week Double-blind Treatment Period and a 4-7...
What is the current status of trial NCT01709214?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 619 participants. The study started on 2012-12-04. Estimated completion is 2014-04-04.
What interventions are being tested in trial NCT01709214?
The interventions under investigation include: Placebo (DRUG), Oxycodone CR (DRUG), Cebranopadol (GRT6005) Low-Dose Range (DRUG), Cebranopadol (GRT6005) High-Dose Range (DRUG).
Who is sponsoring clinical trial NCT01709214?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01709214's enrollment target sits among peer trials
619 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI